Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This is a research study to find out if a drug called blinatumomab is effective for treating
patients with relapsed or refractory (R/R) or measurable residual disease (MRD) CD19-positive
mixed phenotypic acute leukemia (MPAL). Measurable Residual Disease (MRD) means that there
are a small number of cancer cells remaining after treatment